药物诱导的QT延长和torsade de pointes:使用FDA不良事件报告系统数据库的现实世界药监测研究
Dongxuan Li1, Shuang Chai1, Hongli Wang2
1Department of Pharmacy, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Frontiers in pharmacology
|January 8, 2024
概括
这项研究使用FDA数据识别了导致QT延长和Torsade de Pointes (TdP) 的药物. 它强调经常报告的药物和药物类别,有助于临床实践和药物安全意识.
科学领域:
- 药物监督 药物监督 药物监督
- 心脏病学 心脏病学
- 药品安全 药品安全
背景情况:
- 药物诱导的QT延长和Torsade de Pointes (TdP) 是严重的药物不良反应 (ADR).
- 目前对与QT延长和TdP相关的药物缺乏全面的了解.
- 这种知识差距需要对现实世界的数据进行详细分析,以告知临床实践.
研究的目的:
- 确定与QT延长和TdP相关的最频繁报告的药物和药物类别.
- 分析不良事件报告系统数据以检测与药物相关的ADR信号.
- 提供有关不同药物和药物类别的QT延长和TdP风险特征的见解.
主要方法:
- 从FDA不良事件报告系统 (FAERS) 数据库 (2004-2022) 中分析了42,713份报告.
- 识别潜在的罪祸首药物,并计算经常报告的药物和药物类别.
- 不成比例分析用于检测药物不良反应 (ADR) 信号并评估风险特征.
主要成果:
- 确定了1088种潜在的罪祸首药物,其中抗质药物是最多的.
- 富洛塞米德,乙撒利酸,奎蒂亚平,西塔洛普拉姆和美托普罗罗尔是最常见的药物.
- 精神麻醉药和精神麻醉药是最常见的药物类别;西塔洛普拉姆,翁丹塞特龙,埃斯卡托普拉姆,洛佩拉米德和普罗梅他辛显示了最积极的ADR信号.
结论:
- 这项研究提供了与QT延长和TdP相关的药物的现实世界概述.
- 鉴定的罪祸首药物清单,报告比例和ADR信号特征增强了药物安全概况.
- 这些发现可以优化临床实践,并提高患者在药物诱导心脏事件方面的安全性.
相关概念视频
Pharmacovigilance
838
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
838
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
1.0K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.0K
Desensitization and Tachyphylaxis
1.7K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
1.7K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K
Antiepileptic Drugs: Potassium Channel Activators
183
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
183
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
839
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
839


